

Witness Name: Dr Pamela Johnston

Statement No.: WITN7142005

Exhibits: WITN7142006-0014

Dated: 09/01/2023

INFECTED BLOOD INQUIRY

WRITTEN STATEMENT OF DR PAMELA JOHNSTON

I provide this statement on behalf of Tayside Health Board in response to the request under Rule 9 of the Inquiry Rules 2006 dated 20th August 2020.

I, Dr Pamela Johnston, will say as follows: -

Section 1: Introduction

1. Please set out your name, address, date of birth and professional qualifications.

Name: Dr Pamela Johnston

Address: NHS Tayside Headquarters, Ninewells Hospital, Dundee, DD1 9SY

Date of birth: GRO-C 1964

Professional qualifications: MBChB, FRCA

2. Please set out your current role at the Board and your responsibilities in that role.

- Medical Director – NHS Tayside
- UK IBI Lead for NHS Tayside

3. **Please set out the position of your organisation in relation to the hospital/other institution criticised by the witnesses (for example ‘NHS ABC Health Board (“the Board”) operates from Hospital X and Hospital Y (formerly Hospital Z)’).**

NHS Tayside is responsible for healthcare provision for the population of the Tayside area.

Section 2: Response to Criticism(s) by W0150

The criticisms the Board has been asked to respond to are:

4. **At paragraphs 7, 25 and 76 of his witness statement, witness W0150 states that despite assurances given in 1983 by Ninewells Hospital that his son would be able to live his entire life on one kidney functioning at 60%, by 2004 it was failing and the family felt let down. Please comment on this.**
5. **At paragraphs 76 and 77, witness W0150 asserts that had the hospital looked after his son properly and administered follow-up care, the hepatitis C infection would have been picked up earlier and but for this delay, his son would have had more dialysis-free years. Please comment on this.**
6. **At paragraph 77, witness W0150 states that he believes that the hospital’s calculation of 5 years being the amount of time his son could have been dialysis-free was too low. He believes it should have been in the region of 15 to 20 years and also considers the settlement amount of £37,500 too low. Please comment on this.**

In my role as UK IBI lead for the Board I received the aforementioned Rule 9 Request of 20th August 2020. I identified Professor John Dillon and Dr Robert Oswald as the most appropriate persons to consider and respond to the

criticisms made. Their responses are attached as exhibits (WITN7142006 and WITN7142007).

Neither Prof Dillon or Dr Oswald are able, however, to comment on the issue of the level of compensation paid. I understand that **GRO-B** was represented by Drummond Miller, solicitors in the court action and accordingly, it would have been for them to advise **GRO-B** on an appropriate level of settlement.

Section 3: Other Issues

7. If you hold evidence you consider may be relevant to the Inquiry's investigation of the matters set out in its Terms of Reference, please insert here.

None.

Statement of Truth

I believe that the facts stated in this witness statement are true.

Signed

GRO-C

Dated 09/01/2023

Table of exhibits:

| Date | Notes/ Description | Exhibit number |
|-------------|---|-----------------------|
| 21/10/2021 | Report by Professor John Dillon | WITN7142006 |
| 18/08/2022 | Report by Dr Robert Oswald | WITN7142007 |
| 2009 | Swartz GJ et al. New equations to estimate GFR in children with CKD | WITN7142008 |
| 2012 | Ardissino G et al. Puberty is | WITN7141009 |

| | | |
|------|--|-------------|
| | associated with increased deterioration of renal function in patients with KD | |
| 2020 | Haffner D. Strategies for Optimizing Growth in Children With Chronic Kidney Disease | WITN7142010 |
| 2015 | Fabrizi F et al. Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. | WITN7142011 |
| 2019 | Sugrue DM Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. | WITN7142012 |
| 2018 | Furth et al. Estimating Time to ESRD in Children With CKD | WITN7141013 |
| 2012 | Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. | WITN7141014 |